New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
07:09 EDTMRK, NVS, BAYRY, SNY, RBGPFReckitt Benckiser may be frontrunner for Merck unit, Bloomberg reports
Reckitt Benckiser (RBGPF) is said to have an edge over rivals in bidding for Merck's (MRK) over-the-counter health business, Bloomberg reports. Reckitt is competing against Novartis (NVS), Bayer (BAYRY) and Sanofi (SNY), sources say, and could be the frontrunner because it will be able to generate the most cost savings and have fewer antitrust issues than others. Final bids for the Merck unit are expected on April 16 and sources believe the unit could fetch $10B-$12B.Reference Link
News For MRK;NVS;BAYRY;SNY;RBGPF From The Last 14 Days
Check below for free stories on MRK;NVS;BAYRY;SNY;RBGPF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 13, 2014
17:08 EDTSNYSanofi Pastuer annnounces positive results from trial of Fluzone
Subscribe for More Information
16:52 EDTMRKMerck confirms FDA approval of BELSOMRA
Subscribe for More Information
16:19 EDTSNYOn The Fly: Closing Wrap
Subscribe for More Information
15:30 EDTMRKFDA approves Belsomra sleep drug
The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.
13:13 EDTSNYInterMune exploring sale after bids from Sanofi, Roche, Glaxo, Bloomberg says
InterMune (ITMN) is working with its financial advisers Goldman Sachs (GS) and Centerview Partners to evaluate takeover bids it has received from Sanofi (SNY), Roche (RHHBY), GlaxoSmithKline (GSK) and Actelion (ALIOF), said Bloomberg, citing people with knowledge of the matter. The report noted that one of the sources said Sanofi has so far shown the most interest in a deal for InterMune, whose shares are up more than 13% to $51.56 following the first headlines from the report. Reference Link
13:00 EDTSNYInterMune received takeover bids from Sanofi, Roche, Bloomberg says
August 12, 2014
08:52 EDTSNYSanofi launches authorized generic version of Eloxatin through Winthrop US
Subscribe for More Information
August 11, 2014
15:51 EDTSNYMannKind price target raised to $10 from $6.50 at Piper Jaffray
Subscribe for More Information
11:58 EDTSNYMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information
09:06 EDTSNYOn The Fly: Pre-market Movers
HIGHER: PharmAthene (PIP), up 55% after announcing that a Delaware court awarded the company lump sum expectation damages for the value of its lost profits for SIGA Technologies' (SIGA) smallpox antiviral, Tecovirimat... MannKind (MNKD), up 19% after entering exclusive licensing agreement for development and commercialization of Afrezza inhaled insulin with Sanofi (SNY)... Kinder Morgan (KMI), up 19% after announcing it will acquire all of the outstanding equity securities of Kinder Morgan Energy Partners (KMP), Kinder Morgan Management (KMR) and El Paso Pipeline Partners (EPB)... Tesla (TSLA), up 2.7% following upgrade at Deutsche Bank... Achillion (ACHN), up 6% following upgrades at Wells Fargo and at Piper Jaffray... PepsiCo (PEP), up 0.9% following upgrade at UBS. LOWER: Dean Foods (DF), down 8.6% after reporting Q2 losses that were steeper than expected, saying balance of year "appears rocky," which makes it difficult to provide guidance beyond the immediate quarter... Priceline (PCLN), down 0.7% after reporting Q2 revenue that missed expectations, guiding Q3 EPS below consensus... SIGA Technologies, down 31% after ruling in suit with PharmAthene... 2U (TWOU), down 4.3% after downgraded at Goldman.
07:45 EDTSNYMannKind partnership likely to be viewed favorably, says Piper Jaffray
Subscribe for More Information
07:07 EDTSNYIgnyta names Adrian Senderowicz as Chief Medical Officer
Ignyta (RXDX) announced that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and SVP, Clinical Development and Regulatory Affairs. Senderowicz was most recently Vice President, Global Regulatory Oncology at Sanofi (SNY).
06:31 EDTSNYMannKind to host conference call
Conference call to discuss the collaboration with Sanofi about global licensing agreement for development and commercialization of Afrezza will be held on August 11 at 8:30 am. Webcast Link
05:32 EDTBAYRYRegeneron Eylea injection receives EU approval for DME treatment
Subscribe for More Information
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
05:13 EDTSNYSanofi, MannKind announce global licensing agreement for Afrezza
Subscribe for More Information
August 8, 2014
06:51 EDTNVSJudge rules DOJ can pursue Novartis kickback suit, Reuters says
U.S. District Judge Colleen McMahon ruled that the U.S. Department of Justice is allowed to continue its False Claims Act lawsuit versus Novartis regarding allegations that the company used kickbacks to increase sales of medications covered by Medicare and Medicaid, according to Reuters, citing comments from McMahon. Reference Link
August 7, 2014
08:40 EDTSNYSanofi and Immune Design enters licensing agreement for use of GLASStm
Subscribe for More Information
08:38 EDTNVSEnanta's HCV NS5A inhibitor EDP-239 advances into combination studies
Subscribe for More Information
07:42 EDTSNYPOZEN plans to make future employee reductions
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use